MAPT and amyloidosis: Hickman et al. propose the terminology “epileptic preclinical AD” for LOEU patients without cognitive decline and “epileptic prodromal AD” for those with MCI, provided that all analyzed biomarkers demonstrate the presence of amyloid and tau pathology.